Raymond Booth leads research programs aimed at drug discovery and development for central nervous system disorders. Dr. Booth’s laboratory is on track to an Investigational New Drug (IND) Application regarding drug(s) that target brain serotonin receptors for treatment of neuropsychiatric, neurodevelopmental, and neurological disorders, including, autism spectrum disorder, fragile X syndrome (most common known genetic cause of autism), anxiety, epilepsy, and substance use disorder. Development continues to proceed under the auspices of the National Institutes of Health (NIH) and Boston-based pharmaceutical industry partners, including the Northeastern start-up biotech, Seropeutics.
In addition to receptor structure-based design and synthesis of new chemical entities, laboratory drug discovery and development technology includes computational chemistry and molecular modeling, molecular neuropharmacology, pharmacokinetics, and preclinical in vivo behavioral methodologies for development of drug candidates.